Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma. | J Hematol | 2023 | 37692863 | PubTator, text mining | PubMed |
| Amlodipine downregulates gene expression that involved in the signaling pathways of coagulation process in COVID-19 patients: An observational clinical study. | J Adv Pharm Technol Res | 2023 | 37692005 | PubTator, text mining | PubMed |
| A CH2CH3 hinge region enhances the cytotoxicity of anti-CD5 CAR-T cells targeting T cell acute lymphoblastic leukemia. | Int Immunopharmacol | 2023 | 37690234 | PubTator, text mining | PubMed |
| Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD2-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2. | Cancers (Basel) | 2023 | 37686586 | PubTator, text mining | PubMed |
| The Regulation of Ferroptosis by Noncoding RNAs. | Int J Mol Sci | 2023 | 37686142 | PubTator, text mining | PubMed |
| Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities. | Int J Mol Sci | 2023 | 37686020 | PubTator, text mining | PubMed |
| Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7. | Nat Commun | 2023 | 37684239 | PubTator, text mining | PubMed |
| Structural analysis of peptide binding to integrins for cancer detection and treatment. | Biophys Rev | 2023 | 37681100 | PubTator, text mining | PubMed |
| RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. | EClinicalMedicine | 2023 | 37680942 | PubTator, text mining | PubMed |
| Crosstalk between autophagy and metabolic regulation of (CAR) T cells: therapeutic implications. | Front Immunol | 2023 | 37675121 | PubTator, text mining | PubMed |
| CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them. | Hemasphere | 2023 | 37674860 | PubTator, text mining | PubMed |
| Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma. | Mol Ther Oncolytics | 2023 | 37674626 | PubTator, text mining | PubMed |
| Biology of GD2 ganglioside: implications for cancer immunotherapy. | Front Pharmacol | 2023 | 37670947 | PubTator, text mining | PubMed |
| Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis. | Cancer Med | 2023 | 37667978 | PubTator, text mining | PubMed |
| Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer. | BMC Med | 2023 | 37667257 | PubTator, text mining | PubMed |
| Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma. | Exp Ther Med | 2023 | 37664681 | PubTator, text mining | PubMed |
| Genomic signatures and prognosis of advanced stage Chinese pediatric T cell lymphoblastic lymphoma by whole exome sequencing. | Front Pediatr | 2023 | 37664545 | PubTator, text mining | PubMed |
| Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers. | Mol Ther Oncolytics | 2023 | 37663133 | PubTator, text mining | PubMed |
| Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives. | Mol Ther Oncolytics | 2023 | 37663132 | PubTator, text mining | PubMed |
| Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL. | Mol Ther Oncolytics | 2023 | 37663131 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=21